Budhaditya Chatterjee

Budhaditya Chatterjee

Auto-generated profile, based on publicly available information

Budhaditya Chatterjee

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MCMeenakshi Chawla
Meenakshi Chawla
TMTapas Mukherjee
Tapas Mukherjee
ADAlvina Deka
Alvina Deka
BCBudhaditya Chatterjee
Budhaditya Chatterjee
USUday Aditya Sarkar
Uday Aditya Sarkar
SBSoumen Basak
Soumen Basak
Significance: The canonical NF-κB pathway mediates controlled nuclear activation of RelA factors, which induce proinflammatory genes. Uncontrolled RelA activity, however, fuels aberrant intestinal inflammation. What triggers pathological RelA activity in the colitogenic gut remains unclear. The noncanonical NF-κB module typically directs immune organogenesis involving Nfkb2 gene products. We find that this otherwise harmless noncanonical signaling amplifies canonical RelA activity in the inflamed colon in inflammatory bowel disease patients and in colitogenic mice, aggravating gut pathologies. Our work further suggests that noncanonical signaling supplements copious amounts of RelA dimers, whose activation by canonical signaling exacerbates gut inflammation. In sum, we reveal a mechanism regulating disease-associated inflammation and present the noncanonical Nfkb2 pathway as an attractive therapeutic option in inflammatory diseases.

23 April 2015 in eLife
Verified
Journal Article
Open access
BBBalaji Banoth
Balaji Banoth
BCBudhaditya Chatterjee
Budhaditya Chatterjee
BVBharath Vijayaragavan
Bharath Vijayaragavan
MPM V R Prasad
M V R Prasad
PRPayel Roy
Payel Roy
SBSoumen Basak
Soumen Basak
Tissue microenvironment functions as an important determinant of the inflammatory response elicited by the resident cells. Yet, the underlying molecular mechanisms remain obscure. Our systems-level analyses identified a duration code that instructs stimulus specific crosstalk between TLR4-activated canonical NF-κB pathway and lymphotoxin-β receptor (LTβR) induced non-canonical NF-κB signaling. Indeed, LTβR costimulation synergistically enhanced the late RelA/NF-κB response to TLR4 prolonging NF-κB target gene-expressions. Concomitant LTβR signal targeted TLR4-induced newly synthesized p100, encoded by Nfkb2, for processing into p52 that not only neutralized p100 mediated inhibitions, but potently generated RelA:p52/NF-κB activity in a positive feedback loop. Finally, Nfkb2 connected lymphotoxin signal within the intestinal niche in reinforcing epithelial innate inflammatory RelA/NF-κB response to Citrobacter rodentium infection, while Nfkb2−/− mice succumbed to gut infections owing to stromal defects. In sum, our results suggest that signal integration via the pleiotropic NF-κB system enables tissue microenvironment derived cues in calibrating physiological responses.

19 September 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
PRP Roy
P Roy
TMT Mukherjee
T Mukherjee
BCB Chatterjee
B Chatterjee
BVB Vijayaragavan
B Vijayaragavan
BBB Banoth
B Banoth
SBSoumen Basak
Soumen Basak
Environmental drug resistance constitutes a serious impediment for therapeutic intervention in multiple myeloma. Tumor-promoting cytokines, such as tumor necrosis factor (TNF), induce nuclear factor-κB (NFκB)- driven expression of pro-survival factors, which confer resistance in myeloma cells to apoptotic insults from TNF-related apoptosis-inducing ligand (TRAIL) and other chemotherapeutic drugs. It is thought that RelA:p50 dimer, activated from IκBα-inhibited complex in response to TNF-induced canonical NFκB signal, mediates the pro-survival NFκB function in cancerous cells. Myeloma cells additionally acquire gain-of-function mutations in the non-canonical NFκB module, which induces partial proteolysis of p100 into p52 to promote RelB:p52/NFκB activation from p100-inhibited complex during immune cell differentiation. However, role of non-canonical NFκB signaling in the drug resistance in multiple myeloma remains unclear. Here we report that myeloma-associated non-canonical aberrations reinforce pro-survival TNF signaling in producing a protracted TRAIL-refractory state. These mutations did not act through a typical p52 NFκB complex, but completely degraded p100 to reposition RelB under IκBα control, whose degradation during TNF signaling induced an early RelB:p50 containing NFκB activity. More so, autoregulatory RelB synthesis prolonged this TNF-induced RelB:p50 activity in myeloma cells harboring non-canonical mutations. Intriguingly, TNF-activated RelB:p50 dimer was both necessary and sufficient, and RelA was not required, for NFκB-dependent pro-survival gene expressions and suppression of apoptosis. Indeed, high RelB mRNA expressions in myeloma patients correlated with the augmented level of pro-survival factors and resistance to therapeutic intervention. In sum, we provide evidence that cancer-associated mutations perpetuate TNF-induced pro-survival NFκB activity through autoregulatory RelB control and thereby exacerbate environmental drug resistance in multiple myeloma.

23 October 2017 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
TMTapas Mukherjee
Tapas Mukherjee
BCBudhaditya Chatterjee
Budhaditya Chatterjee
ADAtika Dhar
Atika Dhar
SBSachendra S Bais
Sachendra S Bais
MCMeenakshi Chawla
Meenakshi Chawla
SBSoumen Basak
Soumen Basak

6 December 2016 in Science Signaling
Verified
Journal Article
Closed access
PDF file
BCBudhaditya Chatterjee
Budhaditya Chatterjee
BBBalaji Banoth
Balaji Banoth
TMTapas Mukherjee
Tapas Mukherjee
Nandaraj TayeNandaraj Taye
Nandaraj Taye
BVBharath Vijayaragavan
Bharath Vijayaragavan
SBSoumen Basak
Soumen Basak
The nuclear factor κB (NF-κB) transcription factors coordinate the inflammatory immune response during microbial infection. Pathogenic substances engage canonical NF-κB signaling through the heterodimer RelA:p50, which is subjected to rapid negative feedback by inhibitor of κBα (IκBα). The noncanonical NF-κB pathway is required for the differentiation of immune cells; however, cross-talk between both pathways can occur. Concomitantly activated noncanonical signaling generates p52 from the p100 precursor. The synthesis of p100 is induced by canonical signaling, leading to the formation of the late-acting RelA:p52 heterodimer. This cross-talk prolongs inflammatory RelA activity in epithelial cells to ensure pathogen clearance. We found that the Toll-like receptor 4 (TLR4)–activated canonical NF-κB signaling pathway is insulated from lymphotoxin β receptor (LTβR)–induced noncanonical signaling in mouse macrophage cell lines. Combined computational and biochemical studies indicated that the extent of NF-κB–responsive expression of Nfkbia, which encodes IκBα, inversely correlated with cross-talk. The Nfkbia promoter showed enhanced responsiveness to NF-κB activation in macrophages compared to that in fibroblasts. We found that this hyperresponsive promoter engaged the RelA:p52 dimer generated during costimulation of macrophages through TLR4 and LTβR to trigger synthesis of IκBα at late time points, which prevented the late-acting RelA cross-talk response. Together, these data suggest that, despite the presence of identical signaling networks in cells of diverse lineages, emergent cross-talk between signaling pathways is subject to cell type–specific regulation. We propose that the insulation of canonical and noncanonical NF-κB pathways limits the deleterious effects of macrophage-mediated inflammation.

7 May 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
BCBudhaditya Chatterjee
Budhaditya Chatterjee
PRPayel Roy
Payel Roy
USUday Aditya Sarkar
Uday Aditya Sarkar
MZMingming Zhao
Mingming Zhao
YRYashika Ratra
Yashika Ratra
SBSoumen Basak
Soumen Basak
Tumor necrosis factor (TNF) is a pleiotropic cytokine whose primary physiological function involves coordinating inflammatory and adaptive immune responses. However, uncontrolled TNF signaling causes aberrant inflammation and has been implicated in several human ailments. Therefore, an understanding of the molecular mechanisms underlying dynamical and gene controls of TNF signaling bear significance for human health. As such, TNF engages the canonical nuclear factor kappa B (NF-κB) pathway to activate RelA:p50 heterodimers, which induce expression of specific immune response genes. Brief and chronic TNF stimulation produces transient and long-lasting NF-κB activities, respectively. Negative feedback regulators of the canonical pathway, including IκBα, are thought to ensure transient RelA:p50 responses to short-lived TNF signals. The non-canonical NF-κB pathway mediates RelB activity during immune differentiation involving p100. We uncovered an unexpected role of p100 in TNF signaling. Brief TNF stimulation of p100-deficient cells triggered an additional late NF-κB activity consisting of RelB:p50 heterodimers, which modified the TNF-induced gene-expression program. In p100-deficient cells subjected to brief TNF stimulation, RelB:p50 not only sustained the expression of a subset of RelA-target immune response genes but also activated additional genes that were not normally induced by TNF in WT mouse embryonic fibroblasts (MEFs) and were related to immune differentiation and metabolic processes. Despite this RelB-mediated distinct gene control, however, RelA and RelB bound to mostly overlapping chromatin sites in p100-deficient cells. Repeated TNF pulses strengthened this RelB:p50 activity, which was supported by NF-κB-driven RelB synthesis. Finally, brief TNF stimulation elicited late-acting expressions of NF-κB target pro-survival genes in p100-deficient myeloma cells. In sum, our study suggests that the immune-differentiation regulator p100 enforces specificity of TNF signaling and that varied p100 levels may provide for modifying TNF responses in diverse physiological and pathological settings.